Renalytix transitions to U.S. domestic issuer status, adopts new disclosure channels

Renalytix plc

Effective July 1, 2023, Renalytix began filing periodic reports and registration statements on U.S. domestic issuer forms.
Previously qualified as a foreign private issuer; now required to file more detailed and timely disclosures with the SEC.
Company will disseminate material information via SEC filings, press releases, public calls, its website, and LinkedIn.
Investors encouraged to monitor listed channels for potentially material information.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.